{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"241"},{"groupId":"OG001","value":"231"}],"units":"Participants"}],"description":"Participants were considered positive for anti-ramucirumab antibodies \\[anti-drug antibodies (ADA)\\] if the post-treatment sample had an increase of at least 4-fold in titer from the pretreatment values. If the pretreatment value was not detected or was not present, a 1:20 post-treatment titer was required to indicate treatment emergence of ADA.","groups":[{"description":"Ramucirumab 8 mg/kg IV infusion every 2 weeks. BSC: Palliative and supportive care for disease-related symptoms and toxicity associated with treatment as deemed medically necessary and appropriate in the opinion of the investigator.","id":"OG000","title":"Ramucirumab (IMC-1121B) + BSC"},{"description":"Placebo: 8 mg/kg IV infusion every 2 weeks. BSC: Palliative and supportive care for disease-related symptoms and toxicity associated with treatment as deemed medically necessary and appropriate in the opinion of the investigator.","id":"OG001","title":"Placebo + BSC"}],"paramType":"NUMBER","populationDescription":"Participants who received at least 1 dose of study drug and had post-treatment ADA analysis.","reportingStatus":"POSTED","timeFrame":"Prior to treatment and 1 hour post end of infusion for Cycles 1, 4 and 7 (14-day cycles)","title":"Number of Participants With Treatment Emergent Positive Anti-Ramucirumab Response [Serum Anti-Ramucirumab Antibody Assessment (Immunogenicity)]","type":"SECONDARY","unitOfMeasure":"participants"}